EANM guideline for harmonisation on molar activity or specific activity of radiopharmaceuticals: impact on safety and imaging quality

Gert Luurtsema; Verena Pichler; Salvatore Bongarzone; Yann Seimbille; Philip Elsinga; Antony Gee; Johnny Vercouillie

doi:10.1186/s41181-021-00149-6

EANM guideline for harmonisation on molar activity or specific activity of radiopharmaceuticals: impact on safety and imaging quality

Gert Luurtsema^*, Verena Pichler, Salvatore Bongarzone, Yann Seimbille, Philip Elsinga, Antony Gee, Johnny Vercouillie

^*Corresponding author for this work

Radiology & Nuclear Medicine

Research output: Contribution to journal › Article › Academic › peer-review

42 Citations (Scopus)

14 Downloads (Pure)

Abstract

This guideline on molar activity (A_m) and specific activity (A_s) focusses on small molecules, peptides and macromolecules radiolabelled for diagnostic and therapeutic applications. In this guideline we describe the definition of A_m and A_s, and how these measurements must be standardised and harmonised. Selected examples highlighting the importance of A_m and A_s in imaging studies of saturable binding sites will be given, and the necessity of using appropriate materials and equipment will be discussed. Furthermore, common A_m pitfalls and remedies are described. Finally, some aspects of A_m in relation the emergence of a new generation of highly sensitive PET scanners will be discussed.

Original language	English
Article number	34
Journal	EJNMMI Radiopharmacy and Chemistry
Volume	6
Issue number	1
Early online date	9 Oct 2021
DOIs	https://doi.org/10.1186/s41181-021-00149-6
Publication status	Published - 2021

Bibliographical note

Funding Information:
We thank the EANM committees, EANM national delegates for their review, suggestions and comments. The authors (G.L. and P.E.) thank Prof. dr. A.D. Windhorst for sharing his expertise on Am. Preamble : The European Association of Nuclear Medicine (EANM) is a professional non-profit medical association that facilitates communication worldwide among individuals pursuing clinical and research excellence in nuclear medicine. The EANM was founded in 1985. This EANM guideline has been written by members who are selected on the basis of their scientific good standing and active engagement with relevant scientific societies. This guideline is intended to assist professionals to correctly define and measure molar activity (Am) and specific activity (As), discuss common pitfalls and good practice in the production and measurement of radiotracers with high Am and is written in accordance with the recently published consensus nomenclature rules (Coenen et al. 2017). Scope : Several classes of compounds such as small molecules, peptides and macromolecules radiolabelled for diagnostic and therapeutic purposes.

Publisher Copyright:
© 2021, The Author(s).

Access to Document

10.1186/s41181-021-00149-6Licence: CC BY

s41181-021-00149-6Final published version, 1.23 MBLicence: CC BY

Cite this

@article{059cbc5650714839b5a10adda613ee19,

title = "EANM guideline for harmonisation on molar activity or specific activity of radiopharmaceuticals: impact on safety and imaging quality",

abstract = "This guideline on molar activity (Am) and specific activity (As) focusses on small molecules, peptides and macromolecules radiolabelled for diagnostic and therapeutic applications. In this guideline we describe the definition of Am and As, and how these measurements must be standardised and harmonised. Selected examples highlighting the importance of Am and As in imaging studies of saturable binding sites will be given, and the necessity of using appropriate materials and equipment will be discussed. Furthermore, common Am pitfalls and remedies are described. Finally, some aspects of Am in relation the emergence of a new generation of highly sensitive PET scanners will be discussed.",

author = "Gert Luurtsema and Verena Pichler and Salvatore Bongarzone and Yann Seimbille and Philip Elsinga and Antony Gee and Johnny Vercouillie",

note = "Funding Information: We thank the EANM committees, EANM national delegates for their review, suggestions and comments. The authors (G.L. and P.E.) thank Prof. dr. A.D. Windhorst for sharing his expertise on Am. Preamble : The European Association of Nuclear Medicine (EANM) is a professional non-profit medical association that facilitates communication worldwide among individuals pursuing clinical and research excellence in nuclear medicine. The EANM was founded in 1985. This EANM guideline has been written by members who are selected on the basis of their scientific good standing and active engagement with relevant scientific societies. This guideline is intended to assist professionals to correctly define and measure molar activity (Am) and specific activity (As), discuss common pitfalls and good practice in the production and measurement of radiotracers with high Am and is written in accordance with the recently published consensus nomenclature rules (Coenen et al. 2017). Scope : Several classes of compounds such as small molecules, peptides and macromolecules radiolabelled for diagnostic and therapeutic purposes. Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

doi = "10.1186/s41181-021-00149-6",

language = "English",

volume = "6",

journal = "EJNMMI Radiopharmacy and Chemistry",

issn = "2365-421X",

publisher = "Springer Science+Business Media",

number = "1",

}

TY - JOUR

T1 - EANM guideline for harmonisation on molar activity or specific activity of radiopharmaceuticals

T2 - impact on safety and imaging quality

AU - Luurtsema, Gert

AU - Pichler, Verena

AU - Bongarzone, Salvatore

AU - Seimbille, Yann

AU - Elsinga, Philip

AU - Gee, Antony

AU - Vercouillie, Johnny

N1 - Funding Information: We thank the EANM committees, EANM national delegates for their review, suggestions and comments. The authors (G.L. and P.E.) thank Prof. dr. A.D. Windhorst for sharing his expertise on Am. Preamble : The European Association of Nuclear Medicine (EANM) is a professional non-profit medical association that facilitates communication worldwide among individuals pursuing clinical and research excellence in nuclear medicine. The EANM was founded in 1985. This EANM guideline has been written by members who are selected on the basis of their scientific good standing and active engagement with relevant scientific societies. This guideline is intended to assist professionals to correctly define and measure molar activity (Am) and specific activity (As), discuss common pitfalls and good practice in the production and measurement of radiotracers with high Am and is written in accordance with the recently published consensus nomenclature rules (Coenen et al. 2017). Scope : Several classes of compounds such as small molecules, peptides and macromolecules radiolabelled for diagnostic and therapeutic purposes. Publisher Copyright: © 2021, The Author(s).

PY - 2021

Y1 - 2021

N2 - This guideline on molar activity (Am) and specific activity (As) focusses on small molecules, peptides and macromolecules radiolabelled for diagnostic and therapeutic applications. In this guideline we describe the definition of Am and As, and how these measurements must be standardised and harmonised. Selected examples highlighting the importance of Am and As in imaging studies of saturable binding sites will be given, and the necessity of using appropriate materials and equipment will be discussed. Furthermore, common Am pitfalls and remedies are described. Finally, some aspects of Am in relation the emergence of a new generation of highly sensitive PET scanners will be discussed.

AB - This guideline on molar activity (Am) and specific activity (As) focusses on small molecules, peptides and macromolecules radiolabelled for diagnostic and therapeutic applications. In this guideline we describe the definition of Am and As, and how these measurements must be standardised and harmonised. Selected examples highlighting the importance of Am and As in imaging studies of saturable binding sites will be given, and the necessity of using appropriate materials and equipment will be discussed. Furthermore, common Am pitfalls and remedies are described. Finally, some aspects of Am in relation the emergence of a new generation of highly sensitive PET scanners will be discussed.

UR - http://www.scopus.com/inward/record.url?scp=85116846264&partnerID=8YFLogxK

U2 - 10.1186/s41181-021-00149-6

DO - 10.1186/s41181-021-00149-6

M3 - Article

C2 - 34628570

AN - SCOPUS:85116846264

SN - 2365-421X

VL - 6

JO - EJNMMI Radiopharmacy and Chemistry

JF - EJNMMI Radiopharmacy and Chemistry

IS - 1

M1 - 34

ER -

EANM guideline for harmonisation on molar activity or specific activity of radiopharmaceuticals: impact on safety and imaging quality

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this